  Abbreviations, acronyms & symbols   
  ----------------------------------- -----------------------------------------
  AAAs                                = Abdominal aortic aneurysms
  CAD                                 = Coronary artery disease
  CKD                                 = Chronic kidney disease
  COPD                                = Chronic obstructive pulmonary disease
  CT                                  = Computed tomography
  DM                                  = Diabetes mellitus
  EVAR                                = Endovascular aneurysm repair
  ICU                                 = Intensive care unit
  OSR                                 = Open surgery repair
  PAD                                 = Peripheral arterial disease
  SD                                  = Standard deviation

INTRODUCTION
============

Although aneurysms can occur anywhere in the arterial system, approximately 80% of them occur in the abdominal aorta. Therefore, endovascular aortic repair is most commonly performed to treat infrarenal abdominal aortic aneurysms (AAAs)^\[[@r1]\]^.

AAA is associated with rupture and is managed via either open surgery repair (OSR) or endovascular aneurysm repair (EVAR). EVAR has become the first-choice treatment for anatomically-suitable AAAs^\[[@r2]\]^.

Advanced age, male sex, and clinical comorbidities, such as cardiac, renal, or pulmonary impairment, are associated with survival after AAA repair^\[[@r3]\]^.

The aim of this study is to share the rates of complications, secondary interventions, survival, and mortality after EVAR and to compare the outcomes of young and geriatric groups after EVAR in a single-center, retrospective study.

METHODS
=======

Patients that underwent primary EVAR for infrarenal AAA at a single institution were evaluated retrospectively.

This study included 85 patients that were treated between January 2012 and September 2016; 78 patients electively underwent EVAR and seven underwent EVAR as urgent treatment. In total, 72 patients (84.7%) were male and 13 (15.3%) were female (mean age was 71±8.6 years). Patients were followed up for 36 months (3-60 months).

The patients were divided into two groups according to their age: young (aged \< 65 years) and geriatric (aged ≥ 65 years). An informed consent form about the endovascular treatment was obtained from all patients. The study was retrospective and did not require the approval of the local ethics committee. [Table 1](#t1){ref-type="table"} shows the characteristics of the AAA patients that were included in this study. [Figure 1](#f1){ref-type="fig"} shows the descriptive properties of people in this study. And [Table 2](#t2){ref-type="table"} shows the patients' averages in terms of age, aneurysm diameter, neck angle, neck length, right iliac angle, and left iliac angle.

Fig. 1Descriptive Properties

###### 

Patients\' descriptive characteristics.

  Characteristic     Group     Frequency (n)   Percent (%)
  ------------------ --------- --------------- -------------
  Age                Young     18              21.2
  Geriatric          67        78.8            
  Total              85        100             
  Gender             Male      72              84.7
  Female             13        15.3            
  Total              85        100             
  Chronic disease    CAD       45              52.9
  CAD+COPD           20        23.5            
  CAD+COPD+obesity   8         9.4             
  CAD+obesity        5         5.9             
  CAD+PAD            1         1.2             
  COPD               4         4.7             
  Obesity            1         1.2             
  CKD+ CAD+COPD      1         1.2             
  Total              85        100             
  Result             Failure   2               2.4
  Exitus             3         3.5             
  CKD                3         3.5             
  Cure               77        9.6             
  Total              85        100             

CAD=coronary artery disease; CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; PAD=peripheral arterial disease

###### 

Patients\' averages.

                      N    Mean     SD       Min.     Max.
  ------------------- ---- -------- -------- -------- ---------
  Age                 85   71.080   8.656    49.000   85.000
  Aneurysm diameter   85   71.590   12.551   56.000   121.000
  Neck angle          85   64.390   18.447   20.000   110.000
  Neck length         85   14.120   6.132    5.000    25.000
  Right iliac angle   85   50.590   13.875   20.000   90.000
  Left iliac angle    85   50.470   14.426   20.000   95.000

SD=standard deviation

The mean aneurysm diameter was 71.59±12.55 cm and the average neck angle was 64.39°±18.44°. The mean neck length was 14.12±6.13 cm. The mean right external iliac diameter was 7.9±3.1 mm (5-9 mm) and the mean left external iliac diameter was 7.4±2.8 mm (4.5-8 mm) in the treated patients.

The indication for EVAR was based on the patients' comorbidities, aneurysm configuration, and patient's and surgeon's preferences. EVAR is indicated for infrarenal fusiform AAA with diameter ≥ 5 cm, AAA associated with iliac aneurysms with diameter ≥ 3 cm, saccular aneurysms, false aneurysms, and aneurysms with rupture.

EVAR was performed under general anesthesia in 20 patients and under spinal anesthesia in 65 patients. In all patients, both femoral arteries were surgically removed, and stent grafts were placed after a bolus of heparin was administered at 100 IU/kg.

After the stent graft was placed, control aortography was performed to evaluate graft clearance and possible leakage. The following devices were used in EVAR in this study: Endurent™ (Medtronic) in 70 patients (82.3%), Anaconda™ in six (7%), Ovation™ in three (3.5%), Aorfix™ in one (1.1%), and others in five (5.8%). The evaluated outcomes included in-hospital mortality, complications, and reintervention. The primary study outcome was technical success; the secondary endpoints were mortality and secondary intervention. Technical success was defined as the successful delivery and application of the endograft without intentionally involving the renal, internal iliac, or visceral arteries.

All patients' data were analyzed, specifically general patients' characteristics and post-EVAR outcomes, from patients' charts and physicians' follow-up notes. The database included age, sex, comorbidity, and anatomical factor data. The comorbidities we observed included hypertension, diabetes mellitus (DM), coronary artery disease (CAD), peripheral arterial disease (PAD), renal dysfunction, chronic obstructive pulmonary disease (COPD), and obesity.

The following parameters were recorded: age of the patients, diameter of the aneurysms, neck angle, neck length, iliac angles, complications, and mortality. Regarding operative data, we recorded the model of stent used in the surgery, whether any concomitant procedures were performed, and whether there were any intra-operative complications. The follow-up data consisted of the incidence of endoleaks, reinterventions, complications, and mortality.

All patients were imaged with computed tomography (CT) scans at discharge as well as three, six, and 12 months after the primary repair; patients were imaged annually thereafter.

Statistical Methods
-------------------

The data obtained in the study were analyzed using the Statistical Package for Social Sciences software for Windows, version 22.0 (SPSS, Chicago, IL). The following descriptive statistics were used: number, percentage, mean, and standard deviation. The relationships between group variables were tested by chi-squared analysis. Student's t-test was used to compare the quantitative continuous data between the two independent groups. The findings were evaluated at a 95% confidence interval and 5% significance level. Statistical significance was set at a *P*-value of \< 0.05.

RESULTS
=======

The patients' mean age was 71.1 years, with a standard deviation of 8.6 (range: 49-85) years. The young group comprised 21.2% (18) of the total patients, whereas 78.8% (67) of the patients were over 65 years old (the geriatric group). The median follow-up time was 36 months (3-60 months). Forty-five patients (52.9%) had CAD, 20 (23.5%) had CAD + COPD, eight (9.4%) had CAD + COPD + obesity, five (5.9%) had COPD + obesity, one (1.2%) had COPD + PAD, four (4.7%) only had COPD, one (1.2%) had obesity, and one (1.2%) had kidney failure + CAD + COPD ([Table 1](#t1){ref-type="table"}). There was no significant association between sex and age (ᵡ^2^=0.033; *P*-value=0.553). In the young group, 15 (83.3%) patients were male and three (16.7%) were female. Fifty-seven (85.1%) of the geriatric patients were male and 10 (14.9%) were female. There was no statistically significant association between chronic disease and age (ᵡ^2^=8.001; *P*-value=0.333). And there was no statistically significant association between the outcome and age (ᵡ^2^=2.373; *P*-value=0.499) ([Table 3](#t3){ref-type="table"}).

###### 

Distribution by age.

  ----------------------------------------------------------------------------
                      Young     Geriatric   *P*                  
  ------------------- --------- ----------- ------ ------ ------ -------------
  Gender              Male      15          83.3   57     85.1   Χ^2^=0.033\
                                                                 *P*=0.553

  Female              3         16.7        10     14.9          

  Chronic disease     CAD       8           44.4   37     55.2   Χ^2^=8.001\
                                                                 *P*=0.333

  CAD+COPD            4         22.2        16     23.9          

  CAD+COPD +obesıty   3         16.7        5      7.5           

  CAD+obesıty         3         16.7        2      3             

  CAD+PAD             0         \-          1      1.5           

  COPD                0         \-          4      6             

  Obesıty             0         \-          1      1.5           

  CKD+CAD+COPD        0         \-          1      1.5           

  Result              Failure   0           \-     2      3      Χ^2^=2.73\
                                                                 *P*=0.499

  Exitus              0         \-          3      4.5           

  CKD                 0         \-          3      4.5           

  Cure                18        100         59     88.1          
  ----------------------------------------------------------------------------

CAD=coronary artery disease; CKD=chronic kidney disease; COPD=chronic obstructive pulmonary disease; PAD=peripherial arterial disease

The mean preoperative AAA neck length was 14.120 mm (range: 5-25 mm). The angulation of the aortic neck varied from 20° to 110° and the mean angulation was 64.39°. The differences between the patients' averages, in terms of aneurysm diameter, neck angle, neck length, right iliac angle, and left iliac angle, considering their ages were not statistically significant (*P*-value=0.360, 0.178, 0.141, 0.561, and 0.763, respectively) ([Table 4](#t4){ref-type="table"}).

###### 

Patients\' averages by age.

  Characteristic      Young (n=18)   Geriatric(n=67)   *t*      *P*               
  ------------------- -------------- ----------------- -------- -------- -------- -------
  Aneurysm diameter   69.170         9.167             72.240   13.297   -0.921   0.360
  Neck angle          69.610         14.884            62.990   19.147   1.360    0.178
  Neck length         12.220         4.918             14.630   6.355    -1.488   0.141
  Right iliac angle   48.890         12.551            51.040   14.263   -0.583   0.561
  Left iliac angle    51.390         10.955            50.220   15.286   0.303    0.763

SD=standard deviation

Three deaths were reported in the geriatric group on the first day, two of which were due to rupture and the third was due to kidney failure two days after the operation. The resulting mortality rate was 3.5% (3/85). Endoleaks were detected in 25 (29.4%) patients during the procedure ([Figure 2](#f2){ref-type="fig"}).

Fig. 2Endoleak types.

It was also reported renal insufficiency in three people, all of them in the geriatric group; and two of these had ruptured kidneys. Technical success was achieved in all cases except one. Sixty-seven geriatric people underwent EVAR, and only one case was converted to OSR because of a failure to pass the iliac vessels with the stent graft; in this patient, OSR was performed successfully.

The mean intensive care unit (ICU) stay was one day (range: 0-2) and the mean in-hospital stay was three days (range: 1-6).

There was no statistically significant difference in survival rates between the different age groups. After three years, all patients were alive, except those three that died within two days of the operation.

Six (7.05%) patients underwent renal stent implantation during the same procedure. Five patients were treated with iliac balloon stents (5.8%). The secondary intervention rate was 7% (six patients); in the 36-month follow-up, reintervention was performed in six patients. The left iliac graft was extended in two patients, aortic extension was applied to two patients, one patient underwent aneurysmography with OSR, and one patient underwent a femorofemoral bypass. One of these patients was in the young group; all the others (five patients) were in the geriatric group.

Bi-iliac grafts were used in 82 cases. Only three patients were treated with aorto-uni-iliac grafts and one of them underwent a femorofemoral extra-anatomical bypass.

There was no association between age and aneurysm morphology, but more endoleaks, reinterventions, and complications were observed in patients over 65 years old, though these differences were not statistically significant.

DISCUSSION
==========

AAA is more commonly seen in the elderly than in the young, and it mostly affects men. The aim of elective repair is to prevent rupture, which causes mortality. EVAR has been widely used since it was first reported in the 1990s, by Paradi^\[[@r4]\]^. EVAR was first used for ruptured AAAs by Yusuf et al.^\[[@r5]\]^, in 1994.

Once EVAR was established, it was recommended for elderly and high-risk patients. EVAR's promising results made it attractive for treating young people, low-risk patients, and patients with anatomical risks.

Albuquerque et al.^\[[@r6]\]^ reported, on average, an 84% increase in the use of EVAR between 2005 and 2008, whereas Schwarze et al.^\[[@r7]\]^ reported a 162% increase in EVAR for patients over 85 years old. EVAR is less invasive and better tolerated than conventional OSR.

Several randomized controlled trials and large prospective registries reported that in anatomically suitable patients for non-ruptured and ruptured AAAs, EVAR had significant benefits over OSR, regarding early mortality, and had similar medium-term results^\[[@r8],[@r9]\]^. The benefits of EVAR are reduced blood loss, shorter in-hospital stays, and decreased operative mortality compared to open aneurysm repair^\[[@r10],[@r11]\]^.

EVAR needs more secondary interventions, making it necessary to follow up with patients. But EVAR can be performed safely and effectively in both young and geriatric patients. While age is correlated with an increased risk of cardiovascular disease, hypercholesterolemia, and cerebrovascular disease^\[[@r12]\]^, we saw no differences in the rates of these diseases between the young and geriatric groups in our study.

Machado et al.^\[[@r13]\]^ reported that age \> 80 years influences the survival curve in only OSR group. But in a study by Schermerhorn et al.^\[[@r14]\]^, when the age increased, the survival rate decreased, even in the EVAR group. A meta-analysis revealed that octogenarians have higher perioperative and mid-term mortality rates than younger patients^\[[@r15]\]^; however, we found no significant difference in survival rates between the young and geriatric groups.

The main post-EVAR complications are endoleak and reintervention^\[[@r16]\]^. The majority of endoleaks can be treated with endovascular techniques, though sometimes open surgical interventions are required^\[[@r17]\]^, as seen in 25 patients in our study. The majority of Type Ia endoleaks resolved spontaneously without the need for a secondary procedure in the controls. The secondary interventions are generally used to resolve endograft migration and Type I and III endoleaks. Saadi et al.^\[[@r18]\]^ reported that the survival rate free from reinterventions is 96% after 27 months without operative or postoperative deaths. In our study, six (7%) patients (one young, five geriatric) underwent secondary intervention procedures (five endovascular, one OSR); in contrast, the literature states that secondary interventions occur in 7-13.3% of patients^\[[@r13],[@r19]\]^.

The life expectancy of AAA patients is the major factor that determines which therapy should be pursued. EVAR is a safe and effective treatment for AAA with low (1-2%) perioperative mortality^\[[@r20]\]^.

Pol et al.^\[[@r21]\]^ reported that higher mortality and morbidity rates are seen in elderly patients than in younger ones, with aortic stent grafts.

Altaf et al.^\[[@r22]\]^reported a 40% mortality rate among youths over a six-year period and reported that most of these deaths were unrelated to the aneurysm.

Mani et al.^\[[@r23]\]^ reported a five-year survival rate of 69% and a 10-year survival rate of 39.3% after elective EVAR and reported no significant difference in survival between ages. Machado et al.^\[[@r24]\]^ reported a global post-EVAR mortality rate of 1.2%. They reported only two mortalities in the over-80-years-old group and zero mortality in both groups that were younger than 80-years-old. In our study, there was no mortality in the young group and three patients (3.5%) in the geriatric group died from causes related to EVAR, suggesting that age alone can explain the higher mortality rates reported in the literature. There were no statistical differences in the mortality and reinterventions rates between the groups.

Study Limitations
-----------------

The major limitations of this study include the small numbers of patients and the retrospective nature of the analysis. Also, the different types of grafts could affect the results.

CONCLUSİON
==========

Our single-center study shows that it is safe and feasible to repair AAAs via EVAR. Since there were no statistically significant differences in the mortality and reintervention rates between the age groups, EVAR can be used safely in patients of all ages. The advantages of EVAR include that it is a less invasive operative procedure and it generally results in shorter ICU and in-hospital stays than OSR. Reinterventions are the Achilles' heel of this procedure; however, technological improvements should reduce these complications in the near future.
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